Highlights from Twin Cities Ocular Disease Symposium 2019

Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.

Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.

Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.

Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.

Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.

An independent analysis of 600 patients across 20 US optometry offices found contact lens wearers generate 29% to 86% higher annual profits than eyeglasses-only patients.

Coats explains how neurotrophic keratitis, Demodex blepharitis, cosmetic habits, and mucus fishing complicate dry eye disease.

Ashraf Ahmad, MD, explains what's driving rising dry eye rates and why eyelid evaluation is often overlooked.